NTLA Intellia Therapeutics 8-K2021Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
7 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
NTLA 8-K Filings
- 7 Jan 21 Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
- 2 Dec 20 Intellia Therapeutics Announces Proposed Public Offering of Common Stock
- 9 Nov 20 Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
- 5 Nov 20 Intellia Therapeutics Announces Third Quarter 2020 Financial Results
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…